Table 3.

Number and percentage of patients receiving treatment with BAs at the time of study inclusion, and previous treatment

	Actual treatment with BAs				Previous treatment with BAs
	Total, %	RA	AS	PsA	Total, %	RA	AS	PsA
Etanercept	133	23.6%	20.9%	37%	44	12.7%	6.3%	7.9%
	27.3%				9%
Adalimumab	128	21.2%	27.2%	30.3%	52	14.5%	12%	5.5%
	27.3%				10.7%
Infliximab	113	9.7%	36.7%	23.6%	46	8.5%	10.1%	9.7%
	23.2%				9.4%
Golimumab	37	2.4%	13.3%	7.3%	13	3%	1.9%	3%
	7.6%				2.7%
Tocilizumab	25	15.2%	0	0	4	2.4%	0	0
	5.1%				0.8%
Abatacept	24	12.1%	0.6%	1.8%	2	1.2%	0	0
	4.9%				0.4%
Rituximab	12	7.3%	0	0	4	2.4%	0	0
	2.5%				0.8%
Certolizumab pegol	9	5.5%	0	0	2	1.2%	0	0
	1.8%				0.4%
Ustekinumab	1	0	0	0.6%	0	0	0	0
	0.2%

Abbreviations: BAs, biological agents; RA, rheumatoid arthritis; AS, ankylosing spondylitis; PsA, psoriatic arthritis.